Pulpotomy in Mature Permanent Molars Using Biodentine Versus MTA
Launched by CAIRO UNIVERSITY · Mar 25, 2019
Trial Information
Current as of May 29, 2025
Unknown status
Keywords
ClinConnect Summary
* Patients will be clinically and radiographically examined and their eligibility will be assessed.
* Eligible patients will be randomly assigned to one of 2 groups: experimental group (pulpotomy using Biodentine) and the control group (pulpotomy using MTA).
* After adminsrtation of local anesthesia, pulpotomy will be done under rubber dam isolation. The pulp tissue will be removed until the level of the orifices of the canals. After hemostasis is achieved, the capping material will be placed. In the experimental group, the capping material is Biodentine while in the control group, the capp...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aging between 18-40 years old
- • Patients with symptomatic irreversible pulpitis.
- • Radiographically: Absence or slight widening in periodontal ligament space.
- • Systemically- healthy patients (ASA I or II).
- • Patients who agree to attend for recall appointments and provide written consent.
- Exclusion Criteria:
- • Severe marginal periodontitis.
- • Necrotic pulp, pulp polyp, tooth tender to percussion, clinical progression into periapical abscess, fistula.
- • Non-restorable teeth, teeth with internal/external root resorption or root canal calcification.
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Youssef A. Kamal Elalfy, B.D.S.
Principal Investigator
Cairo University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials